{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:51:34Z","timestamp":1791564694463,"version":"4.3.4"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1U19AI181881"],"award-info":[{"award-number":["1U19AI181881"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007812","name":"University of Washington","doi-asserted-by":"publisher","award":["8192"],"award-info":[{"award-number":["8192"]}],"id":[{"id":"10.13039\/100007812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005233","name":"American Nurses Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005233","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008013","name":"University of Texas Medical Branch at Galveston","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["MethodsX"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.mex.2026.103948","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T07:09:02Z","timestamp":1778137742000},"page":"103948","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["NanoLuc-based microneutralization assay for high-throughput detection of neutralizing antibodies against rift valley fever virus"],"prefix":"10.1016","volume":"16","author":[{"given":"Cigdem","family":"Alkan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander N.","family":"Freiberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8318-2783","authenticated-orcid":false,"given":"Tetsuro","family":"Ikegami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mex.2026.103948_bib0001","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1146\/annurev-ento-010715-023819","article-title":"Rift Valley Fever: an emerging Mosquito-Borne disease","volume":"61","author":"Linthicum","year":"2016","journal-title":"Annu. Rev. Entomol."},{"key":"10.1016\/j.mex.2026.103948_bib0002","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01069-24","article-title":"Promotion of order Bunyavirales to class Bunyaviricetes to accommodate a rapidly increasing number of related polyploviricotine viruses","volume":"98","author":"Kuhn","year":"2024","journal-title":"J. Virol."},{"key":"10.1016\/j.mex.2026.103948_bib0003","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3390\/v3050493","article-title":"The pathogenesis of rift valley fever","volume":"3","author":"Ikegami","year":"2011","journal-title":"Viruses."},{"key":"10.1016\/j.mex.2026.103948_bib0004","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.4269\/ajtmh.22-0356","article-title":"Estimation of the minimal Rift Valley Fever virus protective neutralizing antibody titer in Human volunteers immunized with MP-12 vaccine based on protection in a mouse model of disease","volume":"107","author":"Watts","year":"2022","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.mex.2026.103948_bib0005","first-page":"197","article-title":"Active and passive immunization against Rift Valley fever virus infection in Syrian hamsters","volume":"92","author":"Niklasson","year":"1984","journal-title":"Acta Pathol. Microbiol. Immunol. Scand."},{"key":"10.1016\/j.mex.2026.103948_bib0006","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/978-1-0716-4338-9_2","article-title":"Use of Rift Valley fever virus expressing NanoLuc luciferase for the assessment of neutralizing antibodies and antivirals","volume":"2893","author":"Borrego","year":"2025","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.mex.2026.103948_bib0007","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01782-24","article-title":"Novel replication-competent reporter-expressing Rift Valley fever viruses for molecular studies","volume":"99","author":"Nogales","year":"2025","journal-title":"J. Virol."},{"key":"10.1016\/j.mex.2026.103948_bib0008","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jviromet.2017.06.001","article-title":"A novel highly sensitive, rapid and safe Rift Valley fever virus neutralization test","volume":"248","author":"Wichgers Schreur","year":"2017","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.mex.2026.103948_bib0009","doi-asserted-by":"crossref","first-page":"200","DOI":"10.4142\/jvs.2018.19.2.200","article-title":"Packaging of Rift Valley fever virus pseudoviruses and establishment of a neutralization assay method","volume":"19","author":"Li","year":"2018","journal-title":"J. Vet. Sci."},{"key":"10.1016\/j.mex.2026.103948_bib0010","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/s41541-025-01278-8","article-title":"A system to rapidly develop a bunyavirus pseudotyped virus neutralisation assay for pandemic preparedness","volume":"10","author":"Marchesin","year":"2025","journal-title":"NPJ. Vaccines."},{"key":"10.1016\/j.mex.2026.103948_bib0011","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1128\/JVI.80.6.2933-2940.2006","article-title":"Rescue of infectious rift valley fever virus entirely from cDNA, analysis of virus lacking the NSs gene, and expression of a foreign gene","volume":"80","author":"Ikegami","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.mex.2026.103948_bib0012","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1348-0421.2003.tb03424.x","article-title":"Improved recovery of rabies virus from cloned cDNA using a vaccinia virus-free reverse genetics system","volume":"47","author":"Ito","year":"2003","journal-title":"Microbiol. Immunol."},{"key":"10.1016\/j.mex.2026.103948_bib0013","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1128\/JVI.73.1.251-259.1999","article-title":"Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter","volume":"73","author":"Buchholz","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.mex.2026.103948_bib0014","doi-asserted-by":"crossref","first-page":"8274","DOI":"10.1128\/JVI.00476-06","article-title":"NSm and 78-kilodalton proteins of Rift Valley fever virus are nonessential for viral replication in cell culture","volume":"80","author":"Won","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.mex.2026.103948_bib0015","doi-asserted-by":"crossref","first-page":"4988","DOI":"10.1016\/j.vaccine.2013.08.003","article-title":"Immunogenicity of a recombinant Rift Valley fever MP-12-NSm deletion vaccine candidate in calves","volume":"31","author":"Morrill","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.mex.2026.103948_bib0016","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.vaccine.2012.10.118","article-title":"Safety and immunogenicity of recombinant Rift Valley fever MP-12 vaccine candidates in sheep","volume":"31","author":"Morrill","year":"2013","journal-title":"Vaccine"}],"container-title":["MethodsX"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2215016126001664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2215016126001664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:01:01Z","timestamp":1791561661000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2215016126001664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":16,"alternative-id":["S2215016126001664"],"URL":"https:\/\/doi.org\/10.1016\/j.mex.2026.103948","relation":{},"ISSN":["2215-0161"],"issn-type":[{"value":"2215-0161","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NanoLuc-based microneutralization assay for high-throughput detection of neutralizing antibodies against rift valley fever virus","name":"articletitle","label":"Article Title"},{"value":"MethodsX","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mex.2026.103948","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103948"}}